NCT02202226View on ClinicalTrials.gov

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2015

Conditions
Schizophrenia
Interventions
DRUG

Lu AF35700

DRUG

Placebo

Trial Locations (1)

91206

PAREXEL Phase I Unit, Glendale

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02202226 - Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter